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a  b  s  t  r  a  c  t
Introduction: Multiple myeloma (MM) is a common hematologic malignancy with variable
degrees  of immunodeficiency. Disease- and treatment-related compromise of the immune
system  predisposes patients to infections, which are a major cause of morbidity and mor-
tality.
Objective:  We aimed to establish the incidence and main characteristics of infections in MM
patients  treated at our center over a 10-year period.
Method and results: Of the 412 patients retrospectively analyzed, 154 (37.4%) were  docu-
mented  to have at least one episode of infection and were included in this study. A total
of  244 infectious episodes were documented. The most common site of infection was the
lung,  followed by the genitourinary system. The most common infections were  bacterial,
followed  by viral. Escherichia coli were the most common organism. In 160 (65.5%) episodes,
the  organism was not isolated. Thalidomide with dexamethasone was the most common
treatment  regimen, followed by melphalan with dexamethasone. Infection was  the main
cause  of death in 26 (6.3%) out of all 412 patients.
Conclusion: Infections are a notable cause of morbidity and mortality in the clinical course
of  MM patients. By considering patient and disease characteristics, a risk-adapted selection
of  the MM treatment should be employed, with special attention toward patient age and
disease-associated  organ dysfunction. Patient education, access to healthcare and physician
vigilance  are also essential. Vaccination and antimicrobial prophylaxis may be considered
prior  to or during therapy.
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Introduction
Multiple myeloma (MM)  is characterized by the malig-
nant  proliferation of plasma cells, and variable degrees of
immunodeficiency have been associated with the disease.1
Overproduction of monoclonal, non-functional paraprotein
and  suppression of polyclonal B lymphocytes by malignant
plasma cells result in hypogammaglobulinemia. Infiltration of
the bone marrow crowds out normal hematopoiesis, reduces
the  number of functional leukocytes and causes defects in
cell-mediated  immunity by suppressing T lymphocytes and
natural  killer cells.2,3 Recently, patients with monoclonal gam-
mopathy  of undetermined significance have been noted to
have  an increased risk of infections, corroborating the role of
plasma  cell dyscrasias with immunodeficiency.4 In addition,
organ  damage related to disease and therapy-related adverse
effects  also increase susceptibility to infections.5,6
Multiple myeloma is considered a disease of advanced age
(median  age at diagnosis ∼70 years), with several patients
having pre-existing comorbidities, which further increases
the  risk of mortality from infections.7 Development of new
chemotherapeutic agents and treatment strategies have sig-
nificantly improved the survival of MM patients over the
past  few decades, transforming MM into a chronic condi-
tion,  one with multiple relapses and the need for subsequent
salvage therapies, which further decrease cell-mediated
immunity.8–10 Hence, it is important to manage complications
of  the disease and its treatment as patients live longer.
Herein, we  describe the frequency and characteristics of
infections  in MM patients treated at our institution over a 10-
year  period.
Methods
A retrospective chart review was  conducted for patients
diagnosed with MM and/or treated with conventional
chemotherapy for MM  over a 10-year period (from 2008 to
2017)  at the Aga Khan University Hospital, Karachi, Pakistan.
Since  this was  a retrospective chart review, informed consent
was  waived and ethical exemption was  obtained from the
Ethics  Review Committee at the Aga Khan University Hospital.
Patients  were  identified using the International Classification
of  Diseases coding and their charts were  reviewed. Diagnosis
of  MM was  made based on raised monoclonal gammopathy
with an ‘M’  component, percentage of plasma cells in the
bone  marrow (10–30%) and/or evidence of raised serum cal-
cium  level, renal dysfunction, anemia and lytic bone lesions
on  skeletal survey (CRAB) criteria. The diagnosis of infection
was  made based on clinical signs and symptoms, positive
microbiological cultures and/or positive radiological findings
indicative  of infection in the precise clinical context accord-
ing  to standard practice.11 Diagnosis of fungal urinary tract
infection (UTI) was  made using clinical signs/symptoms of UTI
with significant pyuria, but no bacteria on urinalysis or bac-
terial  growth on urine culture, and positive fungal growth in
urine culture. All patients with at least one episode of infec-
tion  during the course of their treatment were included in this
study.
Information was  written on a semi-structured ques-
tionnaire and consisted of demographic and basic patient
characteristics, clinical and laboratorial characteristics of MM
and chemotherapy regimens. Information on the details of
each  infectious episode, including site and infectious organ-
ism,  was  also collected. Any and all information gathered
from  the medical records of patients for the purpose of this
study  was  kept confidential and disclosed only to the pri-
mary  team conducting the study. Lastly, the outcome of these
patients  was  analyzed. All data were  entered into the Statisti-
cal  Package for the Social Sciences (SPSS) version 19 (SPSS Inc.,
Chicago,  IL, USA) to calculate descriptive statistics, standard
deviations and range of all variables.
Results
During the study period, a total of 412 patients were  diag-
nosed  and/or treated for MM at the Aga Khan University
Hospital using conventional chemotherapy. Patients receiv-
ing  high-dose chemotherapy with stem cell transplantation
were not included. One hundred and fifty four (37.4%) patients
were  documented as having had at least one episode of
infection  during the conventional chemotherapy treatment
(which  excluded high-dose chemotherapy with stem cell
transplantation) and were included in the study. The base-
line  details of these 154 patients are displayed in Table 1.
There  were  89 males and 65 females. The median age ± SD
was  59 ± 11.54 years. The most frequent initial clinical pre-
sentation  of MM was  anemia, seen in 101 patients (66%).
This  was  followed by hypercalcemia, in 49 patients (30%),
and  renal failure (serum creatinine ≥2.0 mg/dL), in 42 patients
(27%).  The IgG paraprotein was  the most common secre-
tory  component. The skeletal survey was normal in 38
patients  (24.7%). Sixteen patients (10.4%) had one to two
lytic  lesions at presentation, while 52 patients (33.7%) had
three  or more  lesions. The skeletal survey was  not available
for  48 patients. Bone marrow biopsy results were  available
for  63 patients, all showing plasmacytosis of ≥10% (range:
10–90%).
A  total of 244 infectious episodes were documented, out
of  which 169 (69.3%) were in the outpatient setting, while
75  (30.7%) were in the inpatient setting. The most common
site  of infection was the lung, followed by the genitouri-
nary system (Table 1). The most common infections were
bacterial, followed by viral. One hundred and sixty (65.5%)
infectious episodes were  culture negative. Escherichia coli were
the  most commonly isolated infectious organisms in 28
episodes  (11.5%). Three patients were  diagnosed with fungal
UTIs  with Candida albicans (two patients during the first-line
treatment with thalidomide and dexamethasone and one
patient  during the second-line treatment with cyclophos-
phamide monotherapy). The complete details of infectious
organisms according to the infection sites are given in
Table  2. Of the infectious episodes with positive cultures,
45  infections were attributed to gram negative bacteria,
whereas 30 infections were due to gram positive bacteria.
The  median duration of the follow-up was  28 months (range
2–97  months), calculated from the date of the MM diagnosis
to  the date of the last follow-up. Out of the total of 412 MM
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Median age ± SD (range), years 59 ± 11.54 (31–85)
Age group
<65 years 84 (54.5)
≥65 years 70 (45.5)
Myeloma secretory component
IgG  97 (63.0)
IgA 46 (29.9)
Light chain only 11 (7.1)
Initial myeloma treatment regimens
Thalidomide,  dexamethasone 45 (29.2)
Thalidomide 11 (7.1)
Melphalan, dexamethasone 18 (11.7)
Melphalan 8 (5.2)
VD or VAD 10 (6.5)
Steroids only 8 (5.2)
CTD 6 (4.0)
Lenalidomide, dexamethasone 5 (3.2)
Othera 3 (1.9)
Data not available 40 (26.0)












VD: vincristine, dexamethasone; VAD: vincristine, doxoru-
bicin, dexamethasone; CTD: cyclophosphamide, thalidomide,
dexamethasone.
a 2 patients received CyBorD: cyclophosphamide, bortezomib, dex-
amethasone, 1 patient received C-VAMP: cyclophosphamide,
vincristine, doxorubicin, methylprednisolone.
b Numbers and percentages are from a total of 114 patients for
whom treatment data was available.
c Numbers and percentages are from a total of 244 episodes.
d Majority included skin/soft tissue infections and catheter-site
infections.
patients during the 10-year period, 26 (6.3%) died of infections
(Table  3).
The  initial treatment regimens were  available for only
114  patients. The most frequent treatment regimen was
thalidomide and dexamethasone, followed by melphalan
and  dexamethasone. Eighty-two (72.0%) patients experienced
their  first episode of infection during the first-line treatment,
while  the remaining 32 (28.0%) experienced it during the
second-line treatment (Table 1). The median time from the ini-
tiation  of the MM therapy to the first infectious episode was
127  days.
Discussion
Infections are a major cause of morbidity and mortality in
patients  with MM, severely affecting the ability to treat, treat-
ment  outcomes and survival.12 Vulnerability to infection in
MM  is multifactorial. Key disease-related and therapy-related
factors that contribute to increased susceptibility to infections
are  discussed in detail in previously published articles.5,6
To date, there has been a scarcity of data regarding the
spectrum of infectious complications in patients with MM in
Pakistan. In our 10-year study period, infections occurred in
154 (37.4%) patients. The most frequently isolated organisms
were  E. coli, followed by Staphylococcus aureus, coagulase neg-
ative  Staphylococci and Pseudomonas aeruginosa. We observed
a  greater number of bacterial infections attributed to gram-
negative  bacteria in comparison to gram-positive bacteria, a
finding which is concordant with previous data.13 However,
some  studies have reported gram-positive and gram-negative
bacteria to cause almost an equal number of infections in
MM.5,14,15
There is a substantial increase in the risk of infection within
the  first year following diagnosis (11-fold in bacterial and 18-
fold  in viral infections),10 with the greatest risk of infection
being in the first 2 months of starting therapy and in patients
with  active (particularly relapsed or refractory) disease.13,16
In fact, the MM patient group at highest risk for developing
serious infections is comprised of patients with renal fail-
ure,  with approximately one-third of these patients dying
within  the first 2 months of diagnosis.17 Most infections in
newly  diagnosed, treatment-naïve patients and during the
first  few months of therapy are attributable to Streptococcus
pneumoniae,18 although one must note that this observation
is  reported in older studies. Pneumonia and septic arthritis
are  the most common infections in this subgroup. In fact,
infection is often the initial presentation that leads to the
work-up  and eventual diagnosis of MM in a notable propor-
tion  of patients.13,19–21 In contrast, patients who  develop renal
failure  and those with advanced or relapsed/refractory dis-
ease  suffer from infections mainly due to gram-negative bacilli
or  S. aureus. Several factors, such as prolonged hospitaliza-
tion, indwelling catheters and central lines, chemotherapy
(especially steroid-based regimens or repeated cycles) and
bone  marrow infiltration by MM,  are implicated in these
patients.16,22
Fever in an MM patient due to the disease itself is
exceedingly rare23 and almost always indicates infection and
therefore  should be taken very seriously. A detailed history
and  physical examination to ascertain the possible site of
infection  are paramount. Empiric treatment covering both
encapsulated and gram-negative bacteria should be started
while  awaiting identification of causative organism(s) via
cultures.13 The choice of antibiotics should always be deter-
mined  according to the pattern of antibiotic resistance at each
institution.
The  respiratory tract and genitourinary system were  the
two  most common sites of infection in our study, which is
consistent  with data from previous reports.10,13,19,20 Although
numerous cultures from patients with respiratory tract infec-
tions  were negative for microorganism growth, S. pneumoniae
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Table 2 – Details of 244 infectious episodes in patients with multiple myeloma.
Organism Blood Genitourinary Lung Gastrointestinal Othera Total
Escherichia coli 2 20 2 2 2 28
Pseudomonas aeruginosa 1 1 3 5
Klebsiella pneumoniae 1 1 2
Hemophilus influenza 1 1 2
Acinetobacter species 1 1 2
Proteus mirabilis 2 2
Campylobacter jejuni 2 2
Helicobacter pylori 2 2
Salmonella paratyphi 1 1
Staphylococcus aureus 5 2 2 9
Coagulase negative Staphylococci 4 1 1 1 7
Streptococcus pneumoniae 4 4
Mycobacterium tuberculosis 4 4
Enterococcus species 2 1 3
Streptococcus pyogenes 1 1
Streptococcus oralis 1 1
Micrococcus species 1 1
Plasmodium falciparum 1 1
Herpes zoster 3
Candida albicans 3 3
Culture negative 8 34 68 33 17 160
Total 28 65 87 40 24 244
a Majority included skin/soft tissue infections and catheter-site infections.
Table 3 – Infections directly leading to mortality in 26
patients.







a Both patients developed sepsis secondary to catheter-site
infection.
was  the most commonly isolated organism in our study. S.
pneumoniae,  S. aureus and Hemophilus influenzae are the most
common  causative organisms of respiratory tract infections in
MM.13 As for the genitourinary system, E. coli were the most
frequently isolated organisms from our patients. Historically,
E.  coli and gram-negative species such as Pseudomonas, Pro-
teus  and Klebsiella are the main causative organisms of UTIs
in  patients with MM.13,19
Some studies14,24 report an increased incidence of fungal
infections in patients with MM,  however, only 3 of our patients
suffered  from fungal infections. This might be explained by
the  fact that we excluded all infectious episodes that occurred
during  and after high-dose chemotherapy and autologous
hematopoietic stem cell transplantation, which is compli-
cated  by profound neutropenia and mucositis (well-known
predisposing factors for fungal infections).25 Similar to our
results,  Valković  et al.,14 reported no fungal infections in their
cohort  of non-transplanted patients. Earlier studies have also
reported a low incidence of fungal infections in patients with
MM.19
A notable number of studies discuss the impact of
infections on the outcomes of MM patients and mortality.
Doughney et al.,19 observed a substantial 26% infectious mor-
tality  in their cohort. Perri et al.,16 and Shaikh et al.,24 reported
infectious mortality rates of 17.4% and 17.0%, respectively.
Another study reported an infection-related death rate of
14.5%  in newly diagnosed MM patients undergoing induc-
tion  chemotherapy.8 In fact, a large study involving 3000 MM
patients  reported a staggering 45% early mortality rate (within
6  months of diagnosis/therapy) attributable to infections26 and
another  large study comprised of 9253 patients showed a 22%
mortality  within the first year of MM diagnosis.10 While these
mortality  rates are notable, some studies have stated com-
paratively  lower mortality rates due to infection. For example,
Valković  et al.,14 reported a mortality rate of 9.3% due to infec-
tions.  Offidani et al.,6 stated that only 1 of 85 (1.1%) MM
patients with infections died. A mortality rate of 1.5% was
observed  in patients with MM in a study by Caravita et al.,27
The mortality rate in the present study due to infections was
6.3%,  which is comparable with mortality rates reported in the
literature.
Although  this is first study from Pakistan investigating
the spectrum of infections in patients with MM,  our study
has  limitations due to its retrospective nature. One draw-
back  is a large number of culture negative infectious episodes,
which  may  have led to an underestimation of the frequency
of  causative organisms and an incomplete characterization of
the  spectrum of infections in our study population. Since a
vast  majority of our patients never had their serum beta-2
microglobulin measured (due to financial constraints), stag-
ing  according to the International Staging System could not
be  determined and incorporated into our results. Missing
patient data, especially urinary light chain excretion, made it
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difficult to stage patients according to the Durie-Salmon sys-
tem  as an alternative. Another limitation is the lack of a
control  group, which made it difficult to ascertain disease
and  patient characteristics that may  play important roles
as  predisposing factors to infections. Prospective studies are
recommended, which would effectively eliminate these limi-
tations  and provide an in-depth characterization of infectious
complications in patients with MM.  Furthermore, the inclu-
sion  of a control group may  also help identify risk-factors
associated with infection, which would help direct individu-
alized  patient care and treatment strategies.
Prophylactic antibiotics may  have a potential role in reduc-
ing  the incidence of infection in MM patients. A study by
Oken  et al.,28 showed that antimicrobial prophylaxis with
trimethoprim–sulfamethoxazole (TMP–SFX) during the first 2
months of anti-myeloma treatment significantly decreased
the  risk of bacterial infections (7.1% vs. 42.3% in controls)
and  infectious mortality (3.6% vs. 15.4% in controls). How-
ever,  a relatively newer and larger study from 2012 showed
no  difference in severe bacterial infections between pro-
phylaxis  with ciprofloxacin vs. TMP–SFX vs. observation
only in the first 2 months of treatment.29 Key concerns
with the use of prophylactic antibiotics are the increased
risks of developing Clostridium difficile infections and antibi-
otic  resistance, which recommend against their routine
use.30
Another plausible strategy to reduce the incidence of
infections is to consider preemptive vaccination, especially
with  killed, component and/or conjugated vaccines. However,
since  three quarters of MM patients demonstrate subopti-
mal  humoral immune responses and decreased polyclonal
immunoglobulin synthesis,31 the feasibility and efficacy of
vaccination  in this patient population is uncertain. Even in the
patients  who are able to mount a humoral immune response
to  vaccination, the antibody response is short-lived. This was
shown  in a study that reported a decline in antibody titers
to  pre-immunization levels within 18 months after vaccina-
tion  with the pneumococcal vaccine.32 One possible strategy
is  to vaccinate MM patients more  frequently than the nor-
mal  population. Since vaccination is relatively less expensive
and  less toxic, exploration of its use as a prophylactic mea-
sure  in future studies is warranted and may yield positive
findings.
The  first step in managing infections in patients with
MM  is a risk-adapted selection of the MM treatment which
takes  under consideration the patient and MM characteristics,
with  special attention towards patient age and disease asso-
ciated  organ dysfunction. Patient education, 24 hour access to
healthcare advice and treatment, and physician vigilance are
all essential in preventing and managing infections in patients
with  MM.  The decision to vaccinate and administer antimicro-
bial  prophylaxis should be determined based on these factors,
as  well as the choice of the anti-myeloma treatment. These
measures  may  lead to individualized preventive measures to
reduce infection risk in MM patients while keeping negative
consequences, such as the risk of resistance development with
prophylactic  antibiotic use and adverse reactions to vaccines,
to  a minimum.
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